IV immunoglobulin (IVIG) is a valid maintenance therapy option for myasthenia gravis

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1299, 2001-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Myasthenia Gravis: Therapy Is Complex

By  

Pharmaceutical Innovation, Vol. 11, Iss. 2, 2002-03 ,pp. : 30-31

Adis International

Access to resources Recommend Favorite

Patients with common variable immunodeficiency (CVID) requiring IV immunoglobulin (IVIG) therapy have poorer health-related (HR) QOL than individuals with other chronic diseases

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 461, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Immunomodulatory treatment for myasthenia gravis

By  

Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Mouse Models of Myasthenia Gravis

By  

Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. : 2468-2486

Bentham Science Publishers

Access to resources Recommend Favorite

Patients with secondary progressive multiple sclerosis (MS) may not benefit from treatment with IV immunoglobulin G (IVIG)

By  

Inpharma, Vol. 1, Iss. 1457, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite